Celltrion Initiates P-I Study of CT-P59 Against COVID-19 in Korea
Shots:
- The Korean MFDS has approved Celltrion’s IND to initiate a P-I trial of CT-P59 in patients with COVID-19. The company has initiated the enrollment and is set to evaluate the safety- tolerability- efficacy- PK- and immunogenicity of CT-P59 and anticipates the completion of study in Q3’20
- The company anticipates the results of P-II & P-III in patients with mild symptoms- the P-III trial in patients with mod. to sev. COVID-19- and the prevention clinical trial- by the end of 2020
- As part of the prevention study- Celltrion will enroll those who are in close contact with COVID-19 patients and those with no symptoms to evaluate the preventative effects of CT-P59
Ref: Celltrion | Image: Celltrion
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com